GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Jeffrey J WallinDeepak Sampath

Abstract

Docetaxel is a front-line standard-of-care chemotherapeutic drug for the treatment of breast cancer. Phosphoinositide 3-kinases (PI3K) are lipid kinases that regulate breast tumor cell growth, migration, and survival. The current study was intended to determine whether GDC-0941, an orally bioavailable class I selective PI3K inhibitor, enhances the antitumor activity of docetaxel in human breast cancer models in vitro and in vivo. A panel of 25 breast tumor cell lines representing HER2+, luminal, and basal subtypes were treated with GDC-0941, docetaxel, or the combination of both drugs and assayed for cellular viability, modulation of PI3K pathway markers, and apoptosis induction. Drug combination effects on cellular viability were also assessed in nontransformed MCF10A human mammary epithelial cells. Human xenografts of breast cancer cell lines and patient-derived tumors were used to assess efficacy of GDC-0941 and docetaxel in vivo. Combination of GDC-0941 and docetaxel decreased the cellular viability of breast tumor cell lines in vitro but to variable degrees of drug synergy. Compared with nontransformed MCF10A cells, the addition of both drugs resulted in stronger synergistic effects in a subset of tumor cell lines that wer...Continue Reading

References

Oct 1, 1995·Endocrine Reviews·R B Dickson, M E Lippman
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Dumontet, B I Sikic
May 20, 2000·Journal of Mammary Gland Biology and Neoplasia·I H Russo, J Russo
Jun 1, 2002·Science·Lewis C Cantley
Jun 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Alexis A BorisyCurtis T Keith
Mar 16, 2004·Science·Yardena SamuelsVictor E Velculescu
Jul 16, 2004·Cancer Biology & Therapy·Kurtis E BachmanBen Ho Park
Jun 1, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M P MorelliF Ciardiello
Nov 22, 2005·Drugs·Katherine A Lyseng-Williamson, Caroline Fenton
Feb 2, 2006·British Journal of Cancer·B KarakasB H Park
Jan 20, 2007·Cancer Research·Daniela OpelSimone Fulda
Feb 23, 2007·Molecular Cancer Research : MCR·Antoinette HollestelleMieke Schutte
Apr 4, 2007·Annals of the New York Academy of Sciences·Su-Hyeong KimYong-Sang Song
Aug 5, 2008·Cancer Research·Katherine Stemke-HaleBryan T Hennessy
Sep 17, 2008·Oncogene·T L Yuan, L C Cantley
Oct 15, 2008·Molecular Cancer Therapeutics·Richard F RiedelPhillip G Febbo
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evelyn YaoKlaus P Hoeflich
May 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carol O'BrienMark R Lackner
Jun 12, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Laurent SalphatiJeffrey J Wallin
Jul 14, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Siyuan Zhang, Dihua Yu
Jan 12, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nguyen TanLisa D Belmont
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman

❮ Previous
Next ❯

Citations

Mar 26, 2013·Acta Pharmacologica Sinica·Ya-ping YangChun-feng Liu
Feb 13, 2013·Nature Reviews. Clinical Oncology·Jordi RodonJosep Tabernero
Dec 10, 2015·Pharmacology & Therapeutics·F Javier CarmonaMaurizio Scaltriti
May 7, 2013·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Paola FerrariAngelo Carpi
Feb 6, 2015·The Journal of Clinical Investigation·Helin Vakifahmetoglu-NorbergJunying Yuan
Apr 28, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Anna Teresa AlberobelloGiuseppe Giaccone
Feb 9, 2017·Future Medicinal Chemistry·Lixia GaoYong Teng
Mar 7, 2020·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xingrong LiuTimothy P Heffron
Aug 6, 2016·Oncotarget·Simone Di FrancoMatilde Todaro
Apr 11, 2020·Breast Cancer Research and Treatment·Pamela R Drullinsky, Sara A Hurvitz
Mar 13, 2020·Science Translational Medicine·Johanna M SchaferJennifer A Pietenpol
Jun 11, 2014·Cancer Discovery·Clare F MaloneKaren Cichowski
Apr 22, 2014·Molecular Cancer Therapeutics·Rodrigo DienstmannJosep Tabernero
Sep 1, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Boris ShorPuja Sapra
Apr 13, 2017·Cancer Research·Miriam GaggianesiMatilde Todaro
Aug 16, 2014·Cancer Research·Catherine WilsonJeff Settleman
Jan 5, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jie LinKui Lin
May 12, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dejan JuricJosep Tabernero
Aug 14, 2019·Seminars in Cancer Biology·VarRuchi SharmaPanneerselvam Priya
Mar 17, 2021·British Journal of Cancer·Albert Gris-OliverVioleta Serra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis